Equity Profile

GRAL

GRAIL, Inc.

Health CareBiotechnology$2.6B

Aug11Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

GRAIL, Inc. is a biotechnology company focused on early cancer detection using advanced genomic technologies....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a crucial indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth will indicate how well GRAIL is expanding its market presence and product adoption.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GRAL Q2-2026 Earnings Preview

Context

Company Snapshot

GRAIL, Inc. is a biotechnology company focused on early cancer detection using advanced genomic technologies. As part of the health care sector, its innovations could significantly impact cancer diagnosis and treatment, making it a key player in the ongoing fight against cancer.

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

86%

Avg EPS Surprise

+21.34%

Avg Stock Reaction

+1.43%

Last Quarter Recap

In Q1 2026, GRAIL reported an EPS of -$2.29, which was better than the expected -$3.00, marking a positive surprise. However, revenue details were not disclosed, and the stock fell slightly the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for GRAIL's upcoming earnings are mixed, given the lack of analyst estimates and management guidance. Investors will be looking for any signs of progress in revenue and cost management.

Bull Case

If GRAIL continues its trend of beating EPS estimates, it could signal strong operational efficiency and market acceptance of its products, potentially driving the stock higher.

Bear Case

On the other hand, if GRAIL fails to show significant revenue growth or provides weak guidance, it could raise concerns about its long-term viability and lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given GRAIL's history of beating EPS estimates, this number will be crucial for investor confidence and stock performance.

What is the revenue growth rate compared to previous quarters?

Revenue growth is essential for assessing the company's market traction and future prospects, making it a key focus for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate GRAIL's potential for revenue growth based on its recent operational improvements and market trends.

Supporting Evidence

GRAIL has consistently beaten EPS estimates, indicating stronger performance than anticipated.

The options market is pricing a significant move, suggesting traders expect a notable reaction to the earnings report.

Key Risk

If GRAIL reports an EPS better than -$2.00, it could challenge the current cautious outlook and drive the stock higher.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on GRAIL's ability to maintain its EPS beat trend and show meaningful revenue growth.

Bull Confirmed If

An EPS of -$2.00 or better would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS worse than -$3.00 would support the bear case, raising concerns about financial stability.

Pre-Earnings Positioning

Options Market

Implied Move

±18.37%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±18.4% while GRAL has averaged ±5.3% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

69.2%

Calls (138K)P/C Ratio: 1.60Puts (89K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GRAIL beats expectations, history suggests the stock could rise by around 1.9% on the following day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to minimal movement as investors await further clarity.

Miss

A miss could lead to a decline, with historical patterns suggesting a potential drop of around 2.26% or more.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific revenue figures or growth rates compared to previous quarters.
2Updates on product adoption rates and market expansion efforts.
3Management's commentary on cost management and operational efficiency.
4Insights into competitive positioning within the biotechnology sector.
5Any guidance or outlook for future quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

GRAIL, Inc. is a biotechnology company focused on early cancer detection using advanced genomic technologies....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a crucial indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth will indicate how well GRAIL is expanding its market presence and product adoption.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GRAL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

86%

Avg EPS Surprise

+21.34%

Avg Stock Reaction

+1.43%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If GRAIL continues its trend of beating EPS estimates, it could signal strong operational efficiency and market acceptance of its products, potentially driving the stock higher.

Bear Case

On the other hand, if GRAIL fails to show significant revenue growth or provides weak guidance, it could raise concerns about its long-term viability and lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given GRAIL's history of beating EPS estimates, this number will be crucial for investor confidence and stock performance.

What is the revenue growth rate compared to previous quarters?

Revenue growth is essential for assessing the company's market traction and future prospects, making it a key focus for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate GRAIL's potential for revenue growth based on its recent operational improvements and market trends.

Supporting Evidence

GRAIL has consistently beaten EPS estimates, indicating stronger performance than anticipated.

The options market is pricing a significant move, suggesting traders expect a notable reaction to the earnings report.

Key Risk

If GRAIL reports an EPS better than -$2.00, it could challenge the current cautious outlook and drive the stock higher.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on GRAIL's ability to maintain its EPS beat trend and show meaningful revenue growth.

Bull Confirmed If

An EPS of -$2.00 or better would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS worse than -$3.00 would support the bear case, raising concerns about financial stability.

Pre-Earnings Positioning

Options Market

Implied Move

±18.37%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±18.4% while GRAL has averaged ±5.3% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

69.2%

Calls (138K)P/C Ratio: 1.60Puts (89K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GRAIL beats expectations, history suggests the stock could rise by around 1.9% on the following day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to minimal movement as investors await further clarity.

Miss

A miss could lead to a decline, with historical patterns suggesting a potential drop of around 2.26% or more.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific revenue figures or growth rates compared to previous quarters.
2Updates on product adoption rates and market expansion efforts.
3Management's commentary on cost management and operational efficiency.
4Insights into competitive positioning within the biotechnology sector.
5Any guidance or outlook for future quarters.